Download Library

Date	Title	Documents
November 16, 2017	Anthera Corporate Presentation	Add Files Anthera Corporate Presentation 933.7 KB
March 17, 2016	Additional Definitive Proxy Materials	Add Files Additional Definitive Proxy Materials 33.2 KB
March 14, 2016	Form 10-K	Add Files Form 10-K 1.7 MB
June 8, 2015	EULAR 2015 Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient-Reported Outcomes and Disease Activity in Patients with SLE	Add Files EULAR 2015 Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient-Reported Outcomes and Disease Activity in Patients with SLE 727.9 KB
April 9, 2015	Definitive Additional Proxy Materials	Add Files Definitive Additional Proxy Materials 251.3 KB
April 9, 2015	Proxy Statement	Add Files Proxy Statement 704.7 KB
November 18, 2014	Effects of Blisibimod on Patient Reported Outcomes in Patients with SLE - ACR 2014	Add Files Effects of Blisibimod on Patient Reported Outcomes in Patients with SLE - ACR 2014 1.4 MB
October 28, 2014	Anthera Corporate Update	Add Files Anthera Corporate Update 3.3 MB
April 4, 2014	Effects Of Blisibimod On Serum Immunoglobulins and Infection Risk - 2013 ACR Presentation	Add Files Effects Of Blisibimod On Serum Immunoglobulins and Infection Risk - 2013 ACR Presentation 1.2 MB
April 4, 2014	Effects of Chronic Treatment with Sub-cutaneous Blisibimod on Renal and Inflammation Biomarkers - PANLAR 2014	Add Files Effects of Chronic Treatment with Sub-cutaneous Blisibimod on Renal and Inflammation Biomarkers - PANLAR 2014 779.4 KB